A
12.87
-0.83 (-6.06%)
| Previous Close | 13.70 |
| Open | 13.53 |
| Volume | 100,619 |
| Avg. Volume (3M) | 385,346 |
| Market Cap | 828,801,408 |
| Price / Sales | 99.12 |
| Price / Book | 82.76 |
| 52 Weeks Range | |
| Earnings Date | 8 Aug 2025 - 22 Aug 2025 |
| Operating Margin (TTM) | -1,220.88% |
| Diluted EPS (TTM) | -1.62 |
| Quarterly Revenue Growth (YOY) | 118.00% |
| Total Debt/Equity (MRQ) | 106.83% |
| Current Ratio (MRQ) | 1.41 |
| Operating Cash Flow (TTM) | -51.82 M |
| Levered Free Cash Flow (TTM) | -30.61 M |
| Return on Assets (TTM) | -32.84% |
| Return on Equity (TTM) | -103.19% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Adlai Nortye Ltd. | Bullish | Bullish |
AIStockmoo Score
-0.1
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | -0.13 |
|
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 14.25% |
| % Held by Institutions | 0.18% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Smartharvest Portfolios, Llc | 31 Mar 2026 | 16,367 |
| 52 Weeks Range | ||
| Median | 16.00 (24.32%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 13 Feb 2026 | 16.00 (24.32%) | Buy | 9.51 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |